Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with artificial intelligence that provides algorithm-based solutions in a variety of diagnostic testing areas, focusing on patient identification screening, monitoring and prognosis of liver & kidney disease and other chronic conditions. (HBV, HCV, NAFLD, NASH, and ALD).

The company is incorporated in Delaware with a fully-owned subsidiary in Singapore. We are currently commercially active in North America, Asia, Europe and LATAM.​